Through 96 weeks, patients with neovascular age-related macular degeneration required fewer brolucizumab injections compared with aflibercept injections to achieve sustained retinal dryness.
“Brolucizumab had faster and statistically significantly higher rates of complete sustained drying in both studies over the entire trial time frame. This was achieved with fewer doses compared to aflibercept, suggesting better disease control with brolucizumab in neovascular age-related macular degeneration, with the potential for reduced treatment burden,” Carl D. Regillo, MD, said at the
Uncategorized